Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma—a long-term follow-up study
Authors:
Open Access
- 3 April 2012
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 23 (10) , 2670-2675
Abstract
High-dose chemotherapy followed by autologous stem-cell transplantation (HCT–ASCT) is a promising approach in eligible patients with primary central nervous system lymphoma (PCNSL). We report long-term data of patients who were treated according to HCT–ASCT containing protocols. We analyzed survival and relapse rates in 43 (N = 34), 5-year OS and EFS was 82% and 79%, respectively. HCT–ASCT associated related mortality was not observed. Sequential high-dose MTX containing chemotherapy followed by high-dose carmustine/thiotepa plus ASCT (±whole brain irradiation) is safe and leads to high survival rates in eligible patients with newly diagnosed PCNSL.Keywords
This publication has 33 references indexed in Scilit:
- Late relapse in primary central nervous system lymphoma: clonal persistenceNeuro-Oncology, 2011
- Whole-brain radiotherapy in primary CNS lymphomaThe Lancet Oncology, 2011
- Primary CNS lymphoma in patients younger than 60: can whole-brain radiotherapy be deferred?Journal of Neuro-Oncology, 2010
- High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trialThe Lancet Oncology, 2010
- Treatment approaches for primary CNS lymphomasExpert Opinion on Pharmacotherapy, 2010
- High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trialThe Lancet, 2009
- Therapeutic challenges in primary CNS lymphomaThe Lancet Neurology, 2009
- Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factorsJournal of Neuro-Oncology, 2006
- Prospective trial on topotecan salvage therapy in primary CNS lymphomaAnnals of Oncology, 2006
- Trends in survival from primary central nervous system lymphoma, 1975–1999Cancer, 2005